Drug intelligence / Profile preview

fulacimstat

Development stage: Phase 2
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Fulacimstat is a selective, orally available small molecule chymase inhibitor developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction. It has also been investigated for diabetic kidney disease and type 2 diabetes mellitus. Fulacimstat demonstrated safety and tolerability in clinical trials, but did not meet efficacy endpoints in phase II studies. The drug was developed by Bayer HealthCare[3][4][5][7].

Other names: fulacimstat

Targets

CMA1 (Chymase)

Beyond the preview

Go deeper on fulacimstat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulacimstat.

Explore the full profile